Troriluzole
Troriluzole is a novel investigational drug that is being studied for its potential therapeutic effects in various neurological and psychiatric disorders. It is a prodrug of riluzole, which is an established medication used primarily in the treatment of amyotrophic lateral sclerosis (ALS).
Mechanism of Action[edit | edit source]
Troriluzole is designed to modulate the glutamatergic system by reducing the synaptic release of glutamate, an excitatory neurotransmitter. Excessive glutamate activity is implicated in several neurological conditions, and by modulating this pathway, troriluzole aims to provide neuroprotective effects.
Clinical Applications[edit | edit source]
Troriluzole is currently being investigated for its efficacy in treating a variety of conditions, including:
- Generalized anxiety disorder (GAD)
- Obsessive-compulsive disorder (OCD)
- Spinocerebellar ataxia (SCA)
- Alzheimer's disease
Generalized Anxiety Disorder[edit | edit source]
In clinical trials, troriluzole has shown promise in reducing symptoms of generalized anxiety disorder by modulating glutamate levels, which are often dysregulated in anxiety disorders.
Obsessive-Compulsive Disorder[edit | edit source]
Troriluzole is also being studied for its potential to alleviate symptoms of obsessive-compulsive disorder. The drug's ability to modulate glutamate may help in reducing the compulsive behaviors and obsessive thoughts characteristic of OCD.
Spinocerebellar Ataxia[edit | edit source]
Spinocerebellar ataxia is a group of genetic disorders characterized by progressive problems with movement. Troriluzole is being evaluated for its potential to slow the progression of these disorders by protecting neurons from glutamate-induced excitotoxicity.
Alzheimer's Disease[edit | edit source]
Alzheimer's disease is a neurodegenerative disorder marked by cognitive decline. Troriluzole is under investigation for its potential to improve cognitive function and slow disease progression by modulating glutamate activity.
Development and Trials[edit | edit source]
Troriluzole is being developed by Biohaven Pharmaceuticals. The drug has undergone several phases of clinical trials to evaluate its safety, tolerability, and efficacy in various conditions. Results from these trials will determine its potential for approval and use in clinical practice.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
-
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Prab R. Tumpati, MD
